Skip to main navigation Skip to search Skip to main content

X-ray structural study of amyloid-like fibrils of tau peptides bound to small-molecule ligands

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

3 Scopus citations

Abstract

Atomic structures of Tau involved in Alzheimer’s disease complexed with small molecule binders are the first step to define the Tau pharmacophore, leading the way to a structure-based design of improved diagnostics and therapeutics. Yet the partially disordered and polymorphic nature of Tau hinders structural analyses. Fortunately, short segments from amyloid proteins, which exhibit similar biophysical properties to the full-length proteins, also form fibrils and oligomers, and their atomic structures can be determined using X-ray microcrystallography. Such structures were successfully used to design amyloid inhibitors. This chapter describes experimental procedures used to determine crystal structures of Tau peptide segments in complex with small-molecule binders.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages89-100
Number of pages12
DOIs
StatePublished - 2017
Externally publishedYes

Publication series

NameMethods in Molecular Biology
Volume1523
ISSN (Print)1064-3745

Bibliographical note

Publisher Copyright:
© Springer Science+Business Media New York 2017.

Keywords

  • Alzheimer’s disease
  • Amyloid-like peptides
  • Microcrystallography
  • Microcrystals
  • Pharmacophore
  • Small molecules
  • Tau

Fingerprint

Dive into the research topics of 'X-ray structural study of amyloid-like fibrils of tau peptides bound to small-molecule ligands'. Together they form a unique fingerprint.

Cite this